N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 8, 2002, Pages 1058-1062

  Tanigawara, Yusuke ^a,d   Kita, Tomoko ^a   Aoyama, Nobuo ^a   Gobara, Manabu ^a   Komada, Fusao ^a,e   Sakai, Toshiyuki ^b   Kasuga, Masato ^b   Hatanaka, Hisakatsu ^c   Sakaeda, Toshiyuki ^a   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Hyogo Prefectural Institute of Public Health and Consumer Sciences   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e JOSAI UNIVERSITY   (Japan)

Author keywords

Adverse events; Genotype; Healthy subjects; Inflammatory bowel disease; N acetyltransferase 2; Sulfasalazine

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; NAT2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG URINE LEVEL; ENTERITIS; GENOTYPE; HOMOZYGOSITY; HUMAN; JAPAN; PANCREATITIS; PHARMACOGENETICS; SIDE EFFECT; URINALYSIS; WILD TYPE; ACETYLATION; ADULT; AREA UNDER THE CURVE; BLOOD; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; URINE;

ACETYLATION; ADULT; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SULFAPYRIDINE;

EID: 10844279275     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.1058     Document Type: Article

References (19)

1. Klotz U., Clin. Pharmacokinet., 10, 285-302 (1985).
2. Das K. M., Dubin R., Clin. Pharmacokinet., 1, 406-125 (1976).
3. Das K. M., Eastwood M. A., McManuts J. P. A., Sircus W., Gut, 14, 631-641 (1973).
4. Azad A. K., Howes D. T., Piris J., Truelove S. C., Gut, 21, 232-240 (1980).
5. Das K. M., Eastwood M. A., McManus J. P. A., Sircus W., N. Engl. J. Med., 289, 491-495 (1973).
6. Schröder H., Evans D. A. P., Gut, 13, 278-284 (1972).
7. Taffet S. L., Das K. M., Dig. Dis. Sci., 28, 833-842 (1983).
8. Sharp M. E., Wallace S. M., Hindmarsh K. W., Brown M. A., Can. J. Pharmaceutic. Sci., 15, 35-38 (1980).
9. Kita T., Tanigawara Y., Chikazawa S., Hatanaka H., Sakaeda T., Komada F., Iwakawa S., Okumura K., Biol. Pharm. Bull., 24, 544-549 (2001).
10. Okumura K., Kita T., Chikazawa S., Komada F., Iwakawa S., Tanigawara Y., Clin. Pharmacol. Ther., 61, 509-517 (1997).
11. Kita T., Sakaeda T., Adachi S., Sakai T., Aoyama N., Hatanaka H., Kasuga M., Okumura K., Biol. Pharm. Bull., 24, 1176-1180 (2001).
12. Show P. N., Sivner A. L., Aarons L., Houston J. B., J. Chromatogr., 274, 393-397 (1983).
13. Chungi V. S., Rekhi G. S., Shargel L., J. Pharm. Sci., 78, 235-238 (1989).
14. Uchida E., Kai K., Kobayashi S., Oguchi K., Miyazaki Y., Yasuhara H., Jpn. J. Clin. Pharmacol. Ther., 21, 377-389 (1990).
15. Schröder H., Evans D.A.P., J. Med. Genet., 9, 168-171 (1972).
16. Goldstein P. D., Alpers D. H., Keating J. P., J. Pediatr., 95, 638-640 (1979).
17. Schröder H., Campbell D. E. S., Clin. Pharmacol. Ther., 13, 539-551 (1972).
18. Nebert D. W., Pharmacogenetics, 10, 279-290 (2000).
19. Wilmink T., Frick T. W., Drug Saf., 14, 406-423 (1996).